|
Radionuclide |
Activity (mCi) Above
Which Instructions Are Required |
Activity (mCi) Above
Which a Record is Required |
Recommended Duration
of Interruption of Breast-Feeding |
| 18F fludeoxyglucose (18FDG) |
|
|
4 hours*** |
| 67Gallium citrate |
0.04 |
0.2 |
Complete Cessation |
| 99mTc mebrofenin (Choletec) |
|
|
None |
| 99mTc exametazime
(Ceretec) |
4 |
15 |
48 hours |
| 99mTc medronate (MDP) |
30 |
150 |
None |
| 99mTc oxidronate (HDP) |
|
|
|
| 99mTc mertiatide (MAG3) |
30 |
150 |
None |
| 99mTc albumin
aggregated (MAA) |
1.3 |
6.5 |
12 hours |
| 99mTc pentetate (DTPA) |
30 |
150 |
None |
| 99mTc sodium
pertechnetate |
3 |
15 |
4 hours |
| 99mTc red blood cells,
in vivo labeling |
10 |
50 |
12 hours |
| 99mTc red blood cells,
in vitro labeling |
30 |
150 |
None |
| 99mTc sestamibi |
30 |
150 |
None |
| 99mTc sulfur colloid |
7 |
35 |
None |
| 111In leukocytes |
0.2 |
1 |
None |
| 123I sodium iodide |
0.5 |
3 |
Complete Cessation |
| 123I iobenguane (MIBG) |
2 |
10 |
48 hours |
| 131I sodium iodide |
0.0004 |
0.002 |
Complete Cessation |
| 201Thallous chloride |
1 |
5 |
96 hours |
| *** Close contact with
infant should be avoided or restricted to no more than 5 hours in
the first 24 hours after radiopharmaceutical administration |
- The duration of
interruption of breastfeeding is selected to reduce the maximum
dose to a newborn infant to less than 0.1 rem, although the
regulatory limit is 0.5 rem. The actual doses that would be
received by most infants would be far below 0.1 rem. The
physician may use discretion in the recommendation, increasing,
or decreasing the duration of interruption.
- Some nuclides are not
byproduct material and are not regulated by the NRC. Information
is presented for convenience of readers of this guide, who
should be aware of the differences that might exist between
regulations of the NRC and state requirements for non-NRC
regulated material. Agreement State licensees should check with
their state regulations before using these values.
- Activities are
rounded to one significant figure, except when considered
appropriate to use two significant figures. Details of some
calculations are shown on NUREG-1492, "Regulatory Analysis on
Criteria for the Release of Patients Administered Radioactive
Material".
References
1. Kowalsky RJ and Falen SW.
Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 3rd
ed. Washington, DC: American Pharmacists
Association; 2011.
2. Regulatory guide 8.39. Release of Patients
Administered Radioactive Materials. Washington, DC: US Nuclear
Regulatory Commission; April 1997. |
